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Abstract 
Infections of the hip joint are usually of bacterial etiology. Only rarely, an infectious arthritis 
is caused in this localization by viruses or fungi. Native joint infections of the hip are less 
common than infections after implantation of prosthetic devices. Difficulties in prosthetic 
joint infections are, (I) a higher age of patients, and, thus an associated presence of other 
medical risk factors, (II) often long courses of treatment regimes depending on the bacte-
rium and its antibiotic resistance, (III) an increased mortality, and (IV) a high economic bur-
den for removal and reimplantation of an infected prosthetic device. The pathogenic 
mechanisms responsible for articular infections are well studied only for some bacteria, e.g. 
Staphylococcus aureus, while others are only partially understood. Important known bacterial 
properties and microbiological characteristics of infection are the bacterial adhesion on the 
native joint or prosthetic material, the bacterial biofilm formation, the development of small 
colony variants (SCV) as sessile bacterial types and the increasing resistance to antibiotics. 
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Infectious arthritis 
The infection of a joint can occur in different 
ways, (I) via injection or during joint operation 
through direct colonization, (II) by direct contact with 
a neighboring infected site, or (III) by haematogenous 
or lymphogenous seed of the pathogen. Another clas-
sification of bacterial arthritis distinguishes acute, 
chronic and reactive forms, which differ in their type 
of joint infection and their triggering bacteria. Reac-
tive arthritis is a postinfectious complication with no 
need of presence for viable pathogens in the joint. 
While reactive arthritis often simultaneously affect 
several joints, the presence of polyarthritic types of 
non reactive arthritis occur infrequently and then 
mostly as a result of several bacteriaemic phases. 
Among joint infections, the hip is the second 
most frequent localization after the knee joint. Basi-
cally, there are no differences in the bacterial spec-
trum between hip joint infections and those of other 
large joints. Hip joint infections, however, are aggra-
vated by the fact that they can exist over a long time 
with only poor symptoms. An increased rate of infec-
tion occurs in the pre-damaged joint and is also asso-
ciated with particular predispositions of the patients 
(Table 1) [1,2,3]. In particular, a joint prosthesis is a 
high risk predisposition for an infection. Periopera-
tively the initial bacterial entry into the joints may 
occur. On the other hand the implanted foreign mate-
rial causes in addition to the severe joint disease pre-
sent an additional reduction in local resistance, which 
facilitates haematogenous infections. The prosthetic 
materials are also additional binding sites for various 
bacteria, and act as a starting point for prosthetic in-
fections. Thus, in addition to the local conditions, the 
bacterial properties and their specific pathogenity 
have to be considered for understanding the whole 
mechanism of infection. Basically, a too late or not Int. J. Med. Sci. 2009, 6 
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sufficiently cured joint infection can cause trophic and 
functional limitations or can even be the starting point 
of a progressive infection spreading in continuity, 
lymphogenic or haematogenic. In general, the detec-
tion and treatment of acute infectious arthritis is an 
acute emerging situation, in which a delay may pro-
gress to further septic inflammation [2]. 
Table 1: Predisposing factors 
 
 
Bacteria responsible for (hip) joint infections 
Some bacteria have preferences for certain infec-
tion routes and patterns. Infections not related to in-
juries or medical interventions (e.g. intraarticular 
puncture, joint replacement) are mostly resulting 
from often physiologic bacteriaemic periods. The 
most frequently detected pathogens of joint infections 
are staphylococci. Staphylococcus aureus has domi-
nance in acute purulent arthritis while coagu-
lase-negative staphylococci can be found mainly in 
periprosthetic infections and after diagnostic arthro-
scopies. Other gram-positive bacteria as causative 
agents for hip joint infections are streptococci, espe-
cially Streptococcus pyogenes, Enterococcus faecalis and 
Corynebacteria species. 
A large number of different gram-negative rods 
act as infectious agents on joints. The group of en-
terobacteria contains a broad spectrum of pathogens. 
Salmonella enterica, Shigella species, and Yersinia species 
are classically described as pathogens for purulent 
and reactive forms of arthritis. Pseudomonas aeruginosa 
can be found more often in predisposed patients (e.g. 
diabetics). In otherwise healthy people it is associated 
with iatrogenic modes of infection during diagnostic 
procedures. Campylobacter species, however, are classic 
agents of reactive arthritis, as well as the obligate in-
tracellular bacteria Chlamydia trachomatis, Mycoplasma 
pneumoniae, and Ureaplasma urealyticum. From the 
spirochaetales only Borrelia burgdorferi sensu lato is 
relevant. Less commonly identified organisms for 
joint infections often accompanied with osteitis or 
osteomyelitis are Brucella species and Mycobacterium 
tuberculosis. Anaerobes, such as Bacteroides fragilis, are 
rarely found and are usually part of a polymicrobial 
infection. An overview is shown in Table 2. 
Table 2: Bacteria responsible for (hip) joint infections 
 
Pathogenesis 
If bacteria reach into the joint they can bind to a 
large number of different binding molecules. Espe-
cially fibrinogen, extracellular matrix proteins and 
glycosaminoglycans, including fibronectin and 
laminin, are components of the blood plasma, the 
bacteria use adhesion to [4,5]. A large number of bac-
teria specific receptors (adhesins) and adhesion fac-
tors have been described. The intra- and interspecific 
variation of the expression of these bacterial patho-
genity factors can be correlated with the inherent 
bacterial virulence [6,7]. In this large microbiological 
and infectiological field a lot of research is done for 
Staphylococcus aureus. This is also substantiated by the 
production of various cytotoxins and the presence of 
highly effective signaling mechanisms [3]. Another 
bacterial feature is the formation of a biofilm, a poly-
meric matrix of saccharides, primarily described in 
the colonization of foreign material. Biofilm produc-
tion as an important mechanism of pathogenesis can 
be detected for S. aureus, coagulase-negative staphy-Int. J. Med. Sci. 2009, 6 
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lococci,  Pseudomonas aeruginosa and other bacteria 
(Figure 1). It was also shown that bacteria inside the 
biofilm have an increased resistance to the local host 
defenses and to antibiotics [8]. Additionally, through 
the conversion into so-called small colony variants 
(Figure 2) additional modifications of bacterial cells 
develop [9], while significantly reducing treatment 
efficiency and triggering chronic processes. The for-
mation of an inflammatory response, with the local 
generation of cytokines and reactive bacterial and 
host specific metabolic products leads to a joint injury, 
not seldom to irreversible destruction. Thus, effective 
therapy strategies must combine calculated antibiotic 
regimes with local surgical interventions. 
Joint replacement surgery increases the risk of 
infections due to intraoperative bacterial wound con-
tamination, leading to an early onset of the typical 
symptoms. The material of the joint prosthesis is also 
covered by host proteins such as fibrinogen and fi-
bronectin, which in turn facilitates bacterial coloniza-
tion, leading to a delayed type of PJI. The foreign 
material allows not only a surface colonization; it is 
also responsible for a reduction of the local defense 
mechanisms. Among others, it leads to an apoptosis of 
phagocytes surrounding the joint prosthesis; a 
mechanism described as frustrane phagocytosis [10]. 
Reactive arthritis (RA), however, is aseptic and 
usually not erosive. It results from a distant infection 
(usually urethritis or enteritis). Often the reactive ar-
thritis is disseminated and involves multiple joints. 
The immunological mechanism of the frequent asso-
ciation with HLA-B27 is not yet fully understood. 
Using immunological and molecular biological pro-
cedures bacterial antigens can be detected in synovial 
fluid and synovial membrane [11]. Although in some 
studies viable bacteria could be detected [12], in an 
overview of research results it can be concluded that 
bacterial antigenetic material or antigen-antibody 
complexes are haematogenous deposited in the joint. 
This triggers a local inflammatory immune reaction, 
even without local bacterial proliferation [3,13]. 
 
Figure 1: (left) Raster electron microscopy of Staphylococcus aureus from broth culture; (right) Staphylococcus aureus biofilm. 
Images from S. Sailer und I. Chatterjee, Homburg/Saar. 
 
Figure 2: Staphylococcus aureus as normal phenotype 
and as small colony variant (SCV). Note the different 
size and hemolysis (identical molecular pattern). 
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Microbiologic procedures in joint infections 
A differentiation of arthritis is practicable by 
examination of typical laboratory medicine and mi-
crobiology characteristics in joint fluid. In addition to 
the macroscopic parameters (e.g. color, viscosity) the 
gram stain is the fastest test, giving a hint to the trig-
gering agent. Beside the inflammatory parameters, 
such as erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP), and white blood cell count, 
which are nonspecific and do not provide loca-
tion-related information, the synovial fluid leukocyte 
count is a simple, rapid and accurate test. The changes 
in acute joint infections are often more pronounced. 
For a targeted therapy the microbiologic examination 
is the most important step [14]. Thus, joint fluid or 
intraarticular tissue must be obtained before antibiotic 
therapy is started. Swabs, also from intraoperative 
sites should not be sent into the laboratory due to the 
small quantity of carried material. Also swabs or tis-
sue from superficial wounds or fistula often show the 
growth of skin flora and not the relevant bacteria. 
Only isolation of S. aureus from sinus tracts is predic-
tive of the causative pathogen [15]. Especially in PJI an 
operational approach is useful to obtain and examine 
several materials. Although molecular techniques 
h a v e  a  h i g h  v a l u e  a s  a  d i a g n o s t i c  p r o c e d u r e ,  o n l y  
bacterial cultures can complete the diagnostic testing 
by antibiograms. The incubation time of the bacterial 
culture should last 7 days. Slow-growing bacteria as a 
pathogen in question, the presence of bacteria modi-
ficated by antibiotic pretreatment, SCV or biofilm 
production need an extended culture period [16]. 
Both, joint defect formation and chronification, if NJI, 
are not treated quickly and efficiently, and increasing 
mortality, high economic burden for removal of in-
fected joint prosthesis and implant renewing [17] al-
ways require the increased effort in sampling and 
microbiological analysis. 
Infection serology 
In reactive arthritis the cultural detection of 
pathogens is often not possible. This makes serologi-
cal analysis to a method principally necessary to de-
tect antibodies against the causing bacteria. The anti-
body detection has a great diagnostic value also due 
to the reduced sensitivity of bacterial culture in joint 
infections caused by Borrelia or Brucella. For a medi-
cally and economically adequate evaluation in sero-
logic diagnosis the sensitivity and specificity of the 
various methods must be considered. An overview of 
the bacteria that most commonly trigger reactive ar-
thritis is listed in Table 3.  
Table 3: Serodiagnosis of common bacterial agents for postinfectious arthritis 
 
 
Antibiotic therapy 
The therapeutic approach has to be selected in 
accordance with the mode of infection (NJI, PJI, RA), 
the expected or found pathogens, and their resistance. 
It should be remembered that the slowed growth of 
bacteria in a biofilm on surfaces of joint prosthesis 
may additionally reinforces antibiotic resistance 
[18,19]. Responsible for such an increase against an-
tibacterial substances are changes in cell wall synthe-
sis, which limits the effect of beta-lactam antibiotics 
and glycopeptides, and the occurrence of bacterial 
variants with modifications of other metabolic activi-
ties, with implications for the action of quinolones, 
aminoglycosides, and tetracyclines. In principle, the 
spectrum of available antibiotics is limited by the 
specific pharmacokinetic requirements in the treat-
ment of joint infections. This applies particularly to 
chronic infections and prosthesis infections. For an 
overview of common substances and therapeutic re-
gimes, see Table 4. Int. J. Med. Sci. 2009, 6 
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Table 4: Antibiotics for therapy of infectious arthritis (all given dosages are for healthy adults of 70 kg with normal liver and 
kidney function) 
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Acute native joint infectious arthritis 
Essential for sufficient treatment of acute septic 
arthritis is the fast and aggressive therapy with the 
combined application of antimicrobial medication 
and joint lavage. Regarding the duration of treatment, 
there are no controlled studies. The recommendations 
vary for native joint infections between 2-3 weeks and 
6 weeks in the presence of accompanied osteomyelitis 
and / or if the clinical response is only moderate. For 
initial therapy in the presence of clustered gram posi-
tive cocci in microscopic examination and, therefore, 
most likely an infection with S. aureus is the intrave-
nous therapy with a penicillinase-resistant penicillin. 
For gram positive chainlike cocci, thus highly suspi-
cious for a streptococcal infection, penicillin G is em-
pirically given. Most of the gram negative rods have 
their effective therapy initially with a quinolone or a 
second or third generation cephalosporin. In the case 
of a negative gram stain, first or second generation 
cephalosporines (e.g. Cefazolin, Cefuroxime), possi-
bly in combination with an anti-staphylococcal peni-
cillin (e.g. Flucloxacillin), are a calculated approach. If, 
after culture results and / or availability of anti-
biograms the first selected antibiotic regime has to be 
adjusted, then it has to be carried out immediately. 
Prosthetic Joint Infection 
In the treatment of PJI virtually every conceiv-
able form was tried out, antibiotics alone or in com-
bination with debridement and intraarticular lavage, 
the ex- and reimplantation of the prosthesis in one or 
two stages, the arthrodesis or as a last option the 
amputation. In all, however, the prolonged antibiotic 
therapy is a crucial factor. 
An algorithm has been described, suggesting the 
surgical management as a function of the time period 
from surgical intervention till onset of PJI, the type of 
infection, the implant and soft tissue situation and 
existing co-morbidities [20]. From the experience in 
antibiotic therapy of bone and joint infections the re-
quirements for an "ideal drug" may be formulated. 
Beneficial characteristics are bactericidal action, effec-
tive bone and tissue concentrations, opportunity for 
oral sequential therapy, and no adverse side effects. 
Even if these aspects should be included in the selec-
tion of the drug of choice, the finding is, however, that 
(I) for many of these parameters (e.g. antibiotic pene-
tration into the bone) no reliable experimental data 
are available, (II) studies correlating these ideal char-
acteristics with the clinical outcome are largely lack-
ing, (III) there is currently no single substance, which 
fully corresponds to all requirements. 
It was shown that the sole antibiotic therapy for 
early-onset PJI may be curative. For infections with 
staphylococci particularly antibiotic combinations 
with Rifampicin possesses high cure rates. A surgical 
intervention must be always combined with a suffi-
cient antibiotic therapy. Also in this constellation Ri-
fampicin plays in staphylococcal infections a promi-
nent role [21]. For infecti o n s  c a u s e d  b y  M R S A  a n d  
MRSE Teicoplanin and Vancomycin are used. Ex-
tending this repertoire with newer antibiotics, espe-
cially Linezolid, Daptomycin and Tigecyclin were 
introduced for PJI therapy. A valid rating for the 
newest (lipo)glycopeptides Oritavancin, Dalbavancin, 
Telavancin, and for the cephalosporins Ceftobiprol 
and Ceftarolin in treatment of methicillin-resistant 
staphylococci is currently not possible. 
Antibiotic prophylaxis 
The perioperative antibiotic prophylaxis is one of 
the procedures, which clearly demonstrates the re-
duction of infection rate after joint surgery [22,23]. 
Important is the application time before operation, 
about 30–60 min before cutting time. The most widely 
used antibiotics in orthopedic surgery are cepha-
losporins of the first or second generation, like Cefa-
zolin or Cefuroxime. Alternatives in patients with 
beta-lactam allergy are Vancomycin or Clindamycin. 
In hospitals with high prevalence of MRSA Vanco-
mycin is also used. 
Haematogenous infections of the joint prosthesis 
may be due to transient bacteremia. Thus, antibiotic 
prophylaxis during dental procedures or genitouri-
nary tract and gastrointestinal tract interventions are 
useful in order to prevent late-onset prosthetic infec-
tion [24]. 
Discussion 
There are only a few interfaces in medicine of 
such high importance like the interaction between 
surgeons, physicians and microbiologists in the pre-
analytical, analytical and postanalytical phases in the 
diagnosis and treatment of joint infections. This 
process generally requires a coordination and opti-
mization by all parties. Conclusions must be made for 
the samples to be investigated, their required num-
bers and volumes, the sample collection method, time 
and mode of transport, and the communication of 
laboratory results. Each of these items can cause a 
delay or failure in efficient diagnosis and therapy. An 
initially chosen antimicrobial therapy has to be 
adapted on the results of diagnostic procedures, the 
infectious agent detected or most probable, and the 
planned surgical procedure. The bacterial culture in 
the microbiological laboratory, especially for PJI and Int. J. Med. Sci. 2009, 6 
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other infections probably due to slow-growing bacte-
ria require an extended period of 7 to 14 days. Espe-
cially for these bacteria molecular biology procedures 
complete the diagnostic scheme. Finally it should be 
noted that the occurrences of postoperative joint in-
fections should be combined with investigations re-
garding their epidemiological value (e.g. accumula-
tions of a certain pathogen or associations with a cer-
tain type of surgery). These results have a great rele-
vance in detection and prevention of nosocomial in-
fections. 
Abbreviations 
HLA: Human leukocyte antigen; MRSA: Methi-
cillin resistant Staphylococcus aureus; MRSE: Methicil-
lin resistant Staphylococcus epidermidis (coagulase 
negative staphylococci); MSSA: Methicillin sensitive 
Staphylococcus aureus; MSSE: Methicillin sensitive 
Staphylococcus epidermidis (coagulase negative 
staphylococci); NJI: Native joint infection; PJI: Pros-
thetic joint infection; RA: Reactive arthritis; SCV: 
Small colony variants. 
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